The 6 most recent market catalysts affecting $RPRX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 85
Royalty Pharma shares are trading lower amid sympathy with Novartis after that company's pelacarsen phase III trial failed to reach its primary endpoint. The company had signed a $500 million funding agreement with Novartis partner Ionis that would have contributed pelacarsen royalties.
The failure of Novartis's pelacarsen Phase III trial is a significant negative catalyst for Royalty Pharma. The $500 million funding agreement with Ionis, contingent on pelacarsen …
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 55
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $68
TD Cowen analyst Michael Nedelcovych maintained a 'Buy' rating on Royalty Pharma (RPRX) and raised the price target from $65 to $68. This action signals a positive outlook from a p…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 75
Royalty Pharma Announces $100M Agreement To Acquire Zealand Pharma's Rusfertide Economics, Including 1% Global Royalty; $50M At Closing, $50M On First Anniversary
This deal is a significant corporate catalyst for both Royalty Pharma and Zealand Pharma. For Zealand, it provides crucial non-dilutive capital, strengthening its balance sheet and…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 85
Rapid7 shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY2026 adjusted EPS guidance above estimates. Also, multiple analysts raised their respective price targets on the stock.
This headline indicates a strong positive catalyst for Rapid7. Better-than-expected earnings and raised guidance are direct indicators of improved financial health and future growt…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62
JP Morgan analyst Chris Schott has maintained an 'Overweight' rating on Royalty Pharma (RPRX) and raised the price target from $58 to $62. This analyst action signals continued con…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 85
Royalty Pharma Q2 Adj. EPS $1.32 Beats $1.28 Estimate, Sales $674.000M Miss $693.190M Estimate
Royalty Pharma's Q2 earnings present a mixed picture for investors. The beat on adjusted EPS suggests strong profitability and operational efficiency, which is a positive signal. H…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.